Skip to search formSkip to main contentSkip to account menu

staphyloferrin A

Known as: Butanedioic acid, 2,2'-((1-carboxy-1,4-butanediyl)bis(imino(2-oxo-2,1-ethanediyl)))bis(2-hydroxy), N(2),N(5)-di-(1-oxo-3-hydroxy-3,4-dicarboxylbutyl)ornithine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Iron is crucial for many cellular processes including DNA synthesis and respiration. The majority of iron in mammals is in heme… 
2010
2010
....................................................................................................................................................................... ii Preface.......................................................................................................................................................................... iv Table of Contents.........................................................................................................................vii List of Tables ............................................................................................................................................................. xi List of Figures...........................................................................................................................................................xii List of Symbols, Abbreviations and Nomenclature.................................................................................xiv Acknowledgements ............................................................................................................................................ xvii Chapter 1. Introduction ......................................................................................................................................... 1 1.1. Staphylococcus aureus ................................................................................................................................ 1 1.2. Iron in the human host .............................................................................................................................. 2 1.3. Iron uptake in Gram-­‐negative bacteria .............................................................................................. 4 1.4. Iron uptake in Gram-­‐positive bacteria ............................................................................................ 10 1.5. S. aureus iron uptake systems ............................................................................................................. 11 1.5.1. The S. aureus heme uptake system............................................................................................ 12 1.5.2. Siderophore uptake systems........................................................................................................ 16 1.6. Objectives of this thesis.......................................................................................................................... 20 Chapter 2. Methods............................................................................................................................................... 22 2.1. S. aureus growth conditions ................................................................................................................. 22 2.2. Construction of S. aureus mutant strains........................................................................................ 22 2.2.1. Construction of S. aureus isdA::Km............................................................................................ 22 2.2.2. Construction of S. aureus isdE::Km............................................................................................ 23 2.2.3. Site-­‐directed mutagenesis of S. aureus isdE for in vivo assays....................................... 23 2.3. Heme plate bioassays.............................................................................................................................. 24 2.4. Heme-­‐dependent bacterial growth studies in liquid culture................................................. 24 2.5. Peroxidase staining.................................................................................................................................. 24 2.6. Recombinant protein expression systems for non-­‐crystallographic use......................... 25 2.6.1. GST-­‐IsdA site directed mutagenesis and expression for heme scavenging from E. coli........................................................................................................................................................................ 25 2.6.2. Cloning and IsdE protein expression for heme scavenging from E. coli ................... 26 2.6.3. Purification of staphyloferrin A biosynthetic enzymes.................................................... 27 2.7. UV/Visible absorption spectroscopic characterization of heme binding from the cytoplasm of E. coli ........................................................................................................................................... 27 2.8. Staphyloferrin A purification from culture supernatants ....................................................... 28 2.9. Staphyloferrin A in vitro synthesis.................................................................................................... 29 2.10. Determination of ferric-­‐staphyloferrin A concentration ...................................................... 29 2.11. Fluorescence spectroscopy siderophore titrations................................................................. 30 2.12. Cloning, expression and purification for structure determination .................................. 30 2.12.1. Expression of IsdAN and IsdAN variants ............................................................................... 31 2.12.2. Protein expression of IsdE for structure determination............................................... 32 2.12.3. Cloning and protein expression of HtsA for structure determination .................... 32 2.13. Crystallization and structure determination ............................................................................. 33